Table 2 Relationship between preoperative CIPI and PAR levels and clinicopathological features in colorectal cancer patients.
Characteristic | CIPI | p-value2 | PAR | p-value2 | ||||
|---|---|---|---|---|---|---|---|---|
Overall, N = 2891 | < 11.69, N = 1871 | ≥ 11.69, N = 1021 | Overall, N = 2891 | < 6.85, N = 1981 | ≥ 6.85, N = 911 | |||
Gender (n%) | Â | Â | Â | 0.693 | Â | Â | Â | 0.009 |
Fermale | 123 (42.6%) | 78 (41.7%) | 45 (44.1%) | Â | 123 (42.6%) | 74 (37.4%) | 49 (53.8%) | Â |
Male | 166 (57.4%) | 109 (58.3%) | 57 (55.9%) | Â | 166 (57.4%) | 124 (62.6%) | 42 (46.2%) | Â |
Age (n%) | Â | Â | Â | 0.753 | Â | Â | Â | 0.002 |
< 45years | 31 (10.7%) | 19 (10.2%) | 12 (11.8%) |  | 31 (10.7%) | 14 (7.1%) | 17 (18.7%) |  |
>60years | 148 (51.2%) | 94 (50.3%) | 54 (52.9%) | Â | 148 (51.2%) | 113 (57.1%) | 35 (38.5%) | Â |
45-60years | 110 (38.1%) | 74 (39.6%) | 36 (35.3%) | Â | 110 (38.1%) | 71 (35.9%) | 39 (42.9%) | Â |
BMI (n%) | Â | Â | Â | 0.330 | Â | Â | Â | 0.104 |
< 18.5 | 8 (2.8%) | 6 (3.2%) | 2 (2.0%) |  | 8 (2.8%) | 3 (1.5%) | 5 (5.5%) |  |
>28 | 36 (12.5%) | 25 (13.4%) | 11 (10.8%) | Â | 36 (12.5%) | 29 (14.6%) | 7 (7.7%) | Â |
18.5–24 | 129 (44.6%) | 76 (40.6%) | 53 (52.0%) |  | 129 (44.6%) | 86 (43.4%) | 43 (47.3%) |  |
24–28 | 116 (40.1%) | 80 (42.8%) | 36 (35.3%) |  | 116 (40.1%) | 80 (40.4%) | 36 (39.6%) |  |
Smoking (n%) | Â | Â | Â | 0.148 | Â | Â | Â | 0.030 |
No | 197 (68.2%) | 122 (65.2%) | 75 (73.5%) | Â | 197 (68.2%) | 127 (64.1%) | 70 (76.9%) | Â |
Yes | 92 (31.8%) | 65 (34.8%) | 27 (26.5%) | Â | 92 (31.8%) | 71 (35.9%) | 21 (23.1%) | Â |
Drink (n%) | Â | Â | Â | 0.106 | Â | Â | Â | 0.093 |
No | 238 (82.4%) | 149 (79.7%) | 89 (87.3%) | Â | 238 (82.4%) | 158 (79.8%) | 80 (87.9%) | Â |
Yes | 51 (17.6%) | 38 (20.3%) | 13 (12.7%) | Â | 51 (17.6%) | 40 (20.2%) | 11 (12.1%) | Â |
T stage (n%) | Â | Â | Â | 0.076 | Â | Â | Â | 0.056 |
T1 | 18 (6.2%) | 15 (8.0%) | 3 (2.9%) | Â | 18 (6.2%) | 15 (7.6%) | 3 (3.3%) | Â |
T2 | 50 (17.3%) | 32 (17.1%) | 18 (17.6%) | Â | 50 (17.3%) | 40 (20.2%) | 10 (11.0%) | Â |
T3 | 204 (70.6%) | 133 (71.1%) | 71 (69.6%) | Â | 204 (70.6%) | 134 (67.7%) | 70 (76.9%) | Â |
T4 | 17 (5.9%) | 7 (3.7%) | 10 (9.8%) | Â | 17 (5.9%) | 9 (4.5%) | 8 (8.8%) | Â |
N stage (n%) |  |  |  | 0.012 |  |  |  | < 0.001 |
N0 | 190 (65.7%) | 134 (71.7%) | 56 (54.9%) | Â | 190 (65.7%) | 145 (73.2%) | 45 (49.5%) | Â |
N1 | 64 (22.1%) | 36 (19.3%) | 28 (27.5%) | Â | 64 (22.1%) | 35 (17.7%) | 29 (31.9%) | Â |
N2 | 35 (12.1%) | 17 (9.1%) | 18 (17.6%) | Â | 35 (12.1%) | 18 (9.1%) | 17 (18.7%) | Â |
Tumor stage (n%) |  |  |  | 0.020 |  |  |  | < 0.001 |
I | 59 (20.4%) | 41 (21.9%) | 18 (17.6%) | Â | 59 (20.4%) | 48 (24.2%) | 11 (12.1%) | Â |
II | 130 (45.0%) | 93 (49.7%) | 37 (36.3%) | Â | 130 (45.0%) | 97 (49.0%) | 33 (36.3%) | Â |
III | 93 (32.2%) | 50 (26.7%) | 43 (42.2%) | Â | 93 (32.2%) | 52 (26.3%) | 41 (45.1%) | Â |
IV | 7 (2.4%) | 3 (1.6%) | 4 (3.9%) | Â | 7 (2.4%) | 1 (0.5%) | 6 (6.6%) | Â |
Differentiated degree (n%) | Â | Â | Â | 0.922 | Â | Â | Â | 0.605 |
UD/PD | 71 (24.6%) | 44 (23.5%) | 27 (26.4%) | Â | 71 (24.6%) | 45 (22.8%) | 26 (28.6%) | Â |
MD | 211 (73.0%) | 138 (73.8%) | 73 (71.6%) | Â | 211 (73.0%) | 147 (74.2%) | 64 (70.3%) | Â |
WD | 7 (2.4%) | 5 (2.7%) | 2 (2.0%) | Â | 7 (2.4%) | 6 (3.0%) | 1 (1.1%) | Â |
Nerve invasion (n%) | Â | Â | Â | 0.002 | Â | Â | Â | 0.450 |
No | 242 (83.7%) | 166 (88.8%) | 76 (74.5%) | Â | 242 (83.7%) | 168 (84.8%) | 74 (81.3%) | Â |
Yes | 47 (16.3%) | 21 (11.2%) | 26 (25.5%) | Â | 47 (16.3%) | 30 (15.2%) | 17 (18.7%) | Â |
Intravascular tumor emboli (%) | Â | Â | Â | 0.014 | Â | Â | Â | 0.387 |
No | 237 (82.0%) | 161 (86.1%) | 76 (74.5%) | Â | 237 (82.0%) | 165 (83.3%) | 72 (79.1%) | Â |
Yes | 52 (18.0%) | 26 (13.9%) | 26 (25.5%) | Â | 52 (18.0%) | 33 (16.7%) | 19 (20.9%) | Â |
CA-199 |  |  |  | < 0.001 |  |  |  | 0.238 |
High | 32 (11.1%) | 7 (3.7%) | 25 (24.5%) | Â | 32 (11.1%) | 19 (9.6%) | 13 (14.3%) | Â |
Normal | 257 (88.9%) | 180 (96.3%) | 77 (75.5%) | Â | 257 (88.9%) | 179 (90.4%) | 78 (85.7%) | Â |
